| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - An open study evaluated the safety, reactogenicity and immunogenicity of a combined HAV and HBV vaccine in 10 patients with AIH (6 patients aged 1-15 years and four patients aged 16+ years). The vaccine was administered using a three-dose vaccination schedule (0, 1 and 6 months). The vaccine course was well tolerated, safe and did not aggravate the clinical course of the underlying disease. Patents responded with 100% seroconversion for antibody to the HAV vaccine component and geometric mean antibody concentration (GIVIC) comparable to healthy cohorts. Response to the HBV component antigen was comparable to previous reports of HBV vaccination in immune compromised individuals with lower GMC than observed in healthy populations. One month after the third vaccine dose (month 7), all six vaccinees in the 1-15 years age group developed protective levels of anti-HBs as compared to two of the four vaccinees in the 16+ years age group.
- An open study evaluated the safety, reactogenicity and immunogenicity of a combined HAV and HBV vaccine in 10 patients with AIH (6 patients aged 1-15 years and four patients aged 16+ years). The vaccine was administered using a three-dose vaccination schedule (0, 1 and 6 months). The vaccine course was well tolerated, safe and did not aggravate the clinical course of the underlying disease. Patents responded with 100% seroconversion for antibody to the HAV vaccine component and geometric mean antibody concentration (GIVIC) comparable to healthy cohorts. Response to the HBV component antigen was comparable to previous reports of HBV vaccination in immune compromised individuals with lower GMC than observed in healthy populations. One month after the third vaccine dose (month 7), all six vaccinees in the 1-15 years age group developed protective levels of anti-HBs as compared to two of the four vaccinees in the 16+ years age group. (en)
- Pacienti s autoimunitní hepatitidou (AIH) jsou ohroženi exacerbací nebo relapsem v případě onemocnění infekční hepatitidou A (HAV) nebo B (HBV) a zasluhují ochranu očkováním. Hodnotili jsme vhodnost kombinované vakcíny proti HAV a HBV u 10 pacientů s AIH (6 ve věku 1-15 let, 4 ve věku 16+ let). Vakcína byla podávána ve třídávkovém schématu (0, 1 a 6 měsíců), které se ukázalo jako bezpečné, dobře snášené a nezhoršilo AIH. Pacienti odpověděli 100%ní sérokonverzí na HAV složku vakcíny s geometrickým průměrem koncentrace protilátek (GMC) srovnatelným se zdravými kohortami. Odpověď na HBV složku s nižší GMC než u zravých populací je v souladu s předchozími studiemi. Za měsíc po třetí dávce vakcíny si 6/6 očkovaných ve věku 1-15 let vyvinulo protektivní hladiny anti-HBs, zatímco u skupiny 16+ let to byli jen 2/4. (cs)
|
| Title
| - Safety and immunogenicity of a combined vaccine against hepatitis A and B on patients with autoimmune hepatitis
- Safety and immunogenicity of a combined vaccine against hepatitis A and B on patients with autoimmune hepatitis (en)
- Bezpečnost a imunogenicita kombinované vakcíny proti hepatitidě A a B pacientů s autoimunní hepatitidou (cs)
|
| skos:prefLabel
| - Safety and immunogenicity of a combined vaccine against hepatitis A and B on patients with autoimmune hepatitis
- Safety and immunogenicity of a combined vaccine against hepatitis A and B on patients with autoimmune hepatitis (en)
- Bezpečnost a imunogenicita kombinované vakcíny proti hepatitidě A a B pacientů s autoimunní hepatitidou (cs)
|
| skos:notation
| - RIV/00216208:11150/05:00004796!RIV08-MSM-11150___
|
| http://linked.open.../vavai/riv/strany
| |
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/00216208:11150/05:00004796
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - Safety; immunogenicity; combined; vaccine; against; hepatitis; patients; autoimmune; hepatitis (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| - Central European Journal of Public Health
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Špliňo, Miroslav
- Pozler, Oldřich
|
| issn
| |
| number of pages
| |
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)